Regeneron Pharmaceuticals (REGN *) Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. More details

REGN * fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 62.2% below our estimate of its fair value

Earnings are forecast to grow 11.72% per year

Analysts in good agreement that stock price will rise by 31.1%

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

REGN * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Regeneron Pharmaceuticals
Historical stock prices
Current Share Price	US$11,156.00
52 Week High	US$14,275.73
52 Week Low	US$9,420.00
Beta	0.24
1 Month Change	-8.63%
3 Month Change	-19.10%
1 Year Change	17.58%
3 Year Change	-13.50%
5 Year Change	6.84%
Change since IPO	22.92%

Recent updates

Shareholder Returns

	REGN *	MX Biotechs	MX Market
7D	0.5%	0%	0%
1Y	17.6%	0%	0%

Return vs Industry: REGN * matched the MX Biotechs industry which returned 17.1% over the past year.

Return vs Market: REGN * exceeded the MX Market which returned 14.8% over the past year.

Price Volatility

Is REGN *'s price volatile compared to industry and market?
REGN * volatility
REGN * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: REGN *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine REGN *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1988	15,343	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN * fundamental statistics
Market cap	Mex$1.12t
Earnings (TTM)	Mex$77.32b
Revenue (TTM)	Mex$260.80b

14.6x

P/E Ratio

4.3x

P/S Ratio

Is REGN * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REGN * income statement (TTM)
Revenue	US$14.92b
Cost of Revenue	US$8.37b
Gross Profit	US$6.55b
Other Expenses	US$2.12b
Earnings	US$4.42b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	43.48
Gross Margin	43.89%
Net Profit Margin	29.65%
Debt/Equity Ratio	6.3%

How did REGN * perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/05 03:52
End of Day Share Price	2026/06/05 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Regeneron Pharmaceuticals (REGN *) Stock Overview

Rewards

Risk Analysis

Regeneron Pharmaceuticals, Inc. Competitors

CSL

Vertex Pharmaceuticals

Biogen

Gilead Sciences

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc.'s Inmazeb And Maftivimab Recommended For Investigational Use In Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals, Inc. Demonstrates Lynozyfic Monotherapy Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron Pharmaceuticals Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Independent Director recently sold Mex$1.2m worth of stock

First quarter dividend of US$0.94 announced

Recent updates

Regeneron Pharmaceuticals, Inc.'s Inmazeb And Maftivimab Recommended For Investigational Use In Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals, Inc. Demonstrates Lynozyfic Monotherapy Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron Pharmaceuticals Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Independent Director recently sold Mex$1.2m worth of stock

First quarter dividend of US$0.94 announced

First quarter 2026 earnings released: EPS: US$6.99 (vs US$7.58 in 1Q 2025)

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on June 04, 2026

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2026

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals Inc Receives FDA Approval for Otarmeni Gene Therapy for Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Demonstrates Cemdisiran Rapid, Deep And Sustained Disease Control In Generalized Myasthenia Gravis Phase 3 Trial

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Commission Approval for Dupixent to Treat Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the Extension of Dosing Intervals for Eylea Hd

Regeneron Pharmaceuticals, Inc. to Report Q1, 2026 Results on Apr 29, 2026

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Regeneron Pharmaceuticals, Inc. Announces Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Fourth quarter dividend of US$0.94 announced

Full year 2025 earnings released: EPS: US$43.07 (vs US$40.90 in FY 2024)

Regeneron Pharmaceuticals, Inc. Announces Upcoming Presentations from Its Ophthalmology Portfolio and Pipeline At the Virtual Angiogenesis Annual Meeting on February 7, 2026

Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Regeneron Pharmaceuticals, Inc. to Report Q4, 2025 Results on Jan 30, 2026

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Upcoming dividend of US$0.88 per share

Insider recently sold Mex$5.2m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Third quarter 2025 earnings released: EPS: US$14.09 (vs US$12.40 in 3Q 2024)

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals Announces FDA Review Extension for EYLEA HD® Prefilled Syringe and Expanded Indications

Second quarter 2025 earnings released: EPS: US$13.24 (vs US$13.25 in 2Q 2024)

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index

Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass

Investor sentiment deteriorates as stock falls 18%

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors

Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million.

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

First quarter 2025 earnings released: EPS: US$7.58 (vs US$6.70 in 1Q 2024)